Contineum Therapeutics Swings From 27% Premarket Gain to 34% Loss After Mixed Bristol Myers IPF Data

Contineum Therapeutics (NASDAQ: CTNM) shares surged roughly 27% in premarket trading on Monday, October 12, after Bristol Myers Squibb (NYSE: BMY) announced positive Phase 3 results for its ALOFT-IPF trial of admilparant in idiopathic pulmonary fibrosis. Both admilparant and Contineum's lead drug candidate PIPE-791 are LPA1 receptor antagonists targeting the same biological pathway in IPF, making the Bristol Myers win an indirect validation of Contineum's scientific thesis.

The early optimism collapsed once full trial details emerged. Bristol Myers' 60 mg twice-daily dose achieved statistically significant reduction in forced vital capacity decline versus placebo at 52 weeks, but the 120 mg dose failed to reach statistical significance, raising questions about dose-response consistency within the LPA1 drug class. Investors interpreted the mixed dose picture as a reason for caution on Contineum's own program, and CTNM shares reversed sharply during Monday's session, ultimately closing down roughly 34%, according to market data, making it one of the sharpest decliners in a broad micro-cap selloff that day.

Stifel analyst Paul Matteis maintained a Buy rating on CTNM, calling the Bristol Myers Phase 3 success the first large-scale confirmation that LPA1 antagonists work in IPF. Matteis described the divergence between the two doses as an "odd nuance" that could reflect patient heterogeneity and standard trial execution challenges rather than a fundamental problem with the mechanism. PIPE-791 is currently in a Phase 2 trial in IPF, and Contineum separately received a Zacks upgrade to a Buy, or Rank No. 2, on October 12, reflecting growing optimism about its earnings prospects ahead of an estimated October 29 earnings date.